Lewis Asset Management LLC Purchases 291 Shares of Amgen Inc. (NASDAQ:AMGN)

Lewis Asset Management LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 24.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,498 shares of the medical research company’s stock after buying an additional 291 shares during the quarter. Lewis Asset Management LLC’s holdings in Amgen were worth $483,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Trinity Legacy Partners LLC lifted its position in shares of Amgen by 1.6% in the third quarter. Trinity Legacy Partners LLC now owns 15,382 shares of the medical research company’s stock valued at $4,993,000 after buying an additional 239 shares during the last quarter. Tandem Investment Advisors Inc. raised its stake in Amgen by 107.4% in the 3rd quarter. Tandem Investment Advisors Inc. now owns 1,655 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 857 shares during the period. Dudley Capital Management LLC acquired a new stake in Amgen during the 3rd quarter valued at $303,000. ARK Investment Management LLC boosted its position in Amgen by 2.4% during the third quarter. ARK Investment Management LLC now owns 76,614 shares of the medical research company’s stock worth $24,686,000 after purchasing an additional 1,793 shares during the period. Finally, Consolidated Planning Corp increased its holdings in shares of Amgen by 273.7% in the third quarter. Consolidated Planning Corp now owns 2,515 shares of the medical research company’s stock valued at $811,000 after purchasing an additional 1,842 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMGN. UBS Group cut their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Truist Financial cut Amgen from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Barclays lifted their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Stock Up 0.0 %

NASDAQ AMGN opened at $321.91 on Friday. The business has a fifty day moving average price of $323.96 and a two-hundred day moving average price of $316.68. The stock has a market capitalization of $173.04 billion, a PE ratio of 41.22, a PEG ratio of 2.79 and a beta of 0.60. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the company earned $4.96 EPS. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.